COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=49691

Kaijiang Yu

drkaijiang@163.com

2020-02-26

Not recruiting

RCT

Randomized

Parallel

Not reported

single-center

Treatment

1. Aged 18 to 85 years old, 2. It conforms to the diagnostic criteria of severe and critical type in Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (6th Edition) , 3. Sign the informed consent form.

1. Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc., 2. Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor, 3. Continuous use of immunosuppressive agents or organ transplants in the past 6 months, 4. Use in vitro life support (ECMO, ECCO2R), 5. Patients are expected to die within 48 hours, 6. Patients with acute kidney injury and AKI stage 2 or above, 7. Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study.

2

The First Affiliated Hospital of Harbin Medical University

18

85

China

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

30

Inflammation factor;

| Declared number of arm (3.0) differs from found arms (4.0)

Phase 0

[{"arm_notes": "", "treatment_id": 1103, "treatment_name": "Renal replacement therapy", "treatment_type": "Life support", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]